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Clinical and Angiographic Factors Associated With
Asymptomatic Restenosis After Percutaneous
Coronary Intervention
Peter N. Ruygrok, MBChB; Mark W.I. Webster, MBChB; Vincent de Valk, PhD;
Gerrit-Anne van Es, PhD; John A. Ormiston, MBChB;
Marie-Angèle M. Morel, BSc; Patrick W. Serruys, MD, PhD
Background—Angiographic restenosis after percutaneous coronary interventional procedures is more common than
recurrent angina. Clinical and angiographic factors associated with asymptomatic versus symptomatic restenosis after
percutaneous coronary intervention were compared.
Methods and Results—All patients with angiographic restenosis from the BENESTENT I, BENESTENT II pilot,
BENESTENT II, MUSIC, WEST 1, DUET, FINESS 2, FLARE, SOPHOS, and ROSE studies were analyzed.
Multivariate analysis evaluated 46 clinical and angiographic variables, comparing those with and without angina. The
10 studies recruited 2690 patients who underwent percutaneous revascularization and 6-month follow-up angiography
(86% of those eligible). Restenosis (50% diameter stenosis) occurred in 607 patients and was clinically silent in 335
(55%). Male sex (P0.008), absence of antianginal therapy with nitrates (P0.0002) and calcium channel blockers
(P0.02) at 6 months, greater reference diameter after the procedure (P0.04), greater reference diameter at follow-up
(P0.004), and lesser lesion severity (percent stenosis) at 6 months (P0.0004) were univariate predictors of
asymptomatic restenosis. By multivariate analysis, only male sex (P0.04), greater reference diameter at follow-up
(P0.002), and lesser lesion severity at 6 months (P0.0001) were associated with restenosis without angina.
Conclusions—Approximately half of patients with angiographic restenosis have no symptoms. The only multivariate
predictors of silent restenosis at 6 months were male sex, greater reference diameter at follow-up, and lesser lesion
severity on follow-up angiography. (Circulation. 2001;104:2289-2294.)
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Restenosis remains the major shortcoming after percuta-neous intervention, with reported rates, in recent times,
varying between 10% and 40%. A combination of patient
factors, such as diabetes, lesion variables including length
and vessel size, and type of revascularization device, all
influence the likelihood of restenosis.1–4 With the evolution
of core laboratories, such as Cardialysis in Rotterdam, large
databases of clinical and angiographic data provide a unique
opportunity to identify factors that may influence the reste-
notic process.
One consistent observation of studies evaluating patient
outcome after percutaneous coronary interventional proce-
dures is the disparity between the incidence of restenosis in
those patients undergoing systematic angiographic follow-up
6 months after the interventional procedure and the rate of
repeat target lesion revascularization in those with clinical
follow-up and symptom-driven repeat angiography.5,6 The
clinically driven repeat revascularization rate is often 50%
the angiographic restenosis rate, and routine angiography 6
months after the intervention clearly influences the likelihood
of reintervention.7
There is little information on the differences in patient or
lesion characteristics between patients who develop resteno-
sis with recurrent symptoms and those in whom restenosis is
clinically silent. This study evaluates patients from 10 inter-
ventional coronary angioplasty or stent trials, each enrolling
between 102 and 1054 patients, with planned 6-month
follow-up angiography. Multivariate analysis was used to
assess clinical or angiographic factors that might be associ-




Patients enrolled in 10 percutaneous coronary interventional stud-
ies5,6,8–15 undertaken over a period of 9 years who underwent
planned 6-month angiographic follow-up were considered for anal-
ysis. Of these studies, 2 were randomized trials of stent deployment
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versus balloon angioplasty (BENESTENT I, BENESTENT II), 6
were registries of newer stent designs (BENESTENT II pilot, DUET,
FINESS 2, ROSE, SOPHOS, WEST I), 1 assessed the efficacy of
intravascular ultrasound–guided stent implantation (MUSIC), and
another studied the effect of a cholesterol-lowering agent on reste-
nosis rates in patients undergoing balloon angioplasty (FLARE) (for
abbreviations and acronyms see Table 1). The 10 studies are
summarized in Table 2. Baseline characteristics of patients enrolled
in these studies are shown in Table 3. All clinical information was
monitored and forwarded to the core laboratory (Cardialysis, Rot-
terdam) and entered into the study databases. Studies were approved
by institutional ethics committees, and written informed consent was
obtained from all patients.
All patients who underwent 6-month angiographic follow-up and
had complete clinical and angiographic data were analyzed. In the
Benestent II and SOPHOS studies, only those assigned to angio-
graphic follow-up were enrolled. Of interest were those who had no
symptoms of angina at 6-month clinical follow-up and angiographic
restenosis, defined as a 50% diameter stenosis at the treated site.
Forty-six clinical and angiographic factors were entered into a
univariate and multivariate analysis to establish whether any were
predictive of asymptomatic or silent restenosis (Table 4).
Angiographic Analysis
All procedural and follow-up angiograms were sent to the core
laboratory (Cardialysis) and analyzed by the Cardiovascular Angiog-
raphy Analysis System, which was validated previously.16,17 For
each patient, several matched angiographic views were obtained
after intracoronary administration of nitrates. Patients with an un-
successful procedure or without angiographic follow-up were ex-
cluded from the analysis. For patients who had undergone multile-
sion coronary angioplasty, the most severe restenotic lesion at
follow-up was entered into the analysis. The minimal luminal
diameter (MLD) and reference diameter obtained by an interpolated
method were determined on an end-diastolic frame.
Statistical Analysis
Statistical analysis was performed with the SAS version 6.12
software package (SAS Institute). Continuous variables were com-
pared by Student’s t test and the categorical variables by the Fisher’s
exact test. We performed a logistic regression on the dependent
variable Y, where Y1 for patients with asymptomatic restenosis
and Y0 for patients with symptomatic restenosis. As explanatory
variables. We considered 46 clinical and angiographic variables. We
executed a univariate logistic regression defined by the formula
log[P(Y1)/P(Y0)]ABX, where X is the explanatory vari-
able, A the intercept, and B the regression parameter. Multivariate
logistic regression defined by the formula log[P(Y1)/
P(Y0)]AB(1)X(1)B(2)X(2). . .B(n)X(n), with
X(1),. . .,X(n) as the explanatory variables, A the intercept, and
B(1),. . .,B(n) the regression parameters, was then performed. With
the stepwise procedure, a group of explanatory variables was
selected that as a group were multivariately significant. Logistic
regression analysis was also performed for the patients treated with
an intracoronary stent. A value of P0.05 was considered
significant.
Results
In the 10 studies, 4013 lesions were treated in 3774 patients.
In 2 studies (BENESTENT II and SOPHOS), patients were
allocated to 6-month clinical and angiographic follow-up or
clinical follow-up alone; thus, 50% of the patients from
these studies were not included in our analysis. Nineteen
percent of patients declined follow-up angiography, leaving
2690 patients with complete clinical and 6-month angio-
graphic data. Of these patients, restenosis, defined as a50%
diameter stenosis, occurred in 607, giving a restenosis rate of
23%; in 335 patients (55%), this was not associated with
symptoms of angina. Most patients had moderate restenosis;
only 5% had 70% diameter stenosis.
The significant univariate predictors of silent as opposed to
symptomatic restenosis (diameter stenosis 50%) were male
sex, absence of nitrate and calcium channel blocker use at
6-month follow-up, reference diameter after the procedure,
reference diameter at 6-month follow-up, and lesion severity
at 6 months (MLD and percent diameter stenosis) (Table 4).
The cumulative frequency curves for MLD and diameter
stenosis comparing those with symptomatic and asymptom-
atic restenosis are depicted in the Figure. By multivariate
analysis, only male sex (P0.04, OR 1.65, 95% CI 1.02 to
2.70), greater reference diameter at follow-up (P0.002, OR
1.73, 95% CI 1.22 to 2.48), and lesser lesion severity (percent
stenosis) at 6-month follow-up angiography (P0.0001, OR
0.93, 95% CI 0.91 to 0.96) were associated with silent
restenosis.
Mean vessel caliber was smaller in women than men
(reference diameter 2.74 versus 2.88 mm, P0.01), and
women also tended to have a smaller mean MLD than men at
follow-up angiography (MLD 0.97 versus 1.02 mm,
P0.27). There was no difference between women and men
in mean percent diameter stenosis (64.5% versus 64.2%,
P0.87).
An analysis was also performed on patients who were
treated with an intracoronary stent. Of the 1469 patients who
received stents from a variety of manufacturers, 242 devel-
oped restenosis (16%), of whom 58% were asymptomatic (as
opposed to 53% in the balloon group, P0.317). The univar-
iate predictors of asymptomatic restenosis were unstable




Patients Nature of Study Stent Type
BENESTENT I 516 Stent vs balloon Palmaz-Schatz
BENESTENT II pilot 203 Stent registry Heparin-coated PS
BENESTENT II 827 Stent vs balloon Heparin-coated PS
DUET 210 Stent registry Multilink
FINESS 2 156 Stent registry NIR
FLARE 1054 Balloon  fluvastatin
MUSIC 161 Stent (IVUS guided) Heparin-coated PS
ROSE 120 Stent registry BeStent
SOPHOS 425 Stent registry Biodiv Ysio
WEST I 102 Stent registry Multilink
IVUS indicates intravascular ultrasound.
TABLE 1. Abbreviations and Acronyms
BENESTENT Belgium and Netherlands stent study
MUSIC Multicenter Ultrasound Stenting in Coronaries study
WEST West European stent trial
SOPHOS Study of Phosphorylcholine on stents
DUET Evaluation of the ACS-Multilink DUET coronary stent system
FLARE Fluvastatin angioplasty restenosis trial
FINESS 2 First International NIR Endovascular Stent Study
ROSE Registry for optimal stent evaluation
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angina at screening (P0.019), absence of calcium channel
blocker (P0.023) and nitrate (P0.0002) use at 6-month
follow-up, and presence of heparin use at the time of
screening (0.0179). By multivariate analysis, unstable an-
gina at the time of screening (P0.03) and absence of nitrate
use at 6 months (P0.0001) were associated with silent
restenosis.
Discussion
Large studies of patients undergoing percutaneous coronary
intervention with planned 6-month angiographic follow-up
have identified the clinical and angiographic predictors of
restenosis. These studies have also demonstrated that angio-
graphic restenosis is more frequent than clinically driven
repeat target lesion revascularization. This analysis demon-
strates that 50% of patients with angiographic restenosis
have no symptoms of angina 6 months after the intervention.
Our finding that 55% of patients with restenosis were
asymptomatic is similar to the 48% reported in the study by
Hernandez et al,18 which was a rigorous evaluation of 277
consecutive patients with restenosis after balloon angioplasty.
Earlier studies reporting a lower proportion of asymptomatic
restenosis have major design limitations, including small
numbers of patients, incomplete angiographic follow-up, and
variable time to follow-up angiography.19–21
In this series of patients enrolled in 10 percutaneous
intervention studies, the overall restenosis was 23%; only
20% of those with restenosis had 70% diameter stenosis.
Univariate predictors of asymptomatic restenosis were male
sex and absence of antianginal medication use, greater
reference diameter after the procedure, greater reference
diameter at follow-up, and lesser lesion severity at 6-month
follow-up. By multivariate analysis, only male sex, reference
diameter at follow-up, and lesser lesion severity at 6 months
were associated with asymptomatic restenosis. This suggests
that there are more similarities between symptomatic and
asymptomatic patients with restenosis than there are impor-
tant differences.
Previous studies have demonstrated that the angiographic
MLD rather than percent diameter stenosis predicts recurrent
symptoms after coronary intervention, with a threshold of
1.35 to 1.50 mm.22,23 This is consistent with our finding that
men were more likely than women to have restenosis without
symptoms, because the women in this study had smaller-
caliber arteries than men, no difference in percent diameter
stenosis, and a trend toward a smaller MLD.
Other factors relating to attitude and perception of pain
may also play a role. Several studies have documented a sex
bias in referral for diagnostic procedures and treatment of
patients with coronary artery disease.24–27 The initial diagno-
sis of angina in women is made more slowly than in men,
because chest pain is often attributed to other causes.27 After
intervention, however, men may experience less pain, may
experience pain that they do not identify as a recurrence of
angina, or may not admit to recurrent symptoms. Alterna-
tively, women, once proven to have coronary artery disease,
may present earlier with recurrent angina. A combination of
these factors may contribute to the sex difference.
Absence of use of nitrates and calcium channel blockers at
follow-up was a univariate predictor of asymptomatic reste-
nosis. Although recurrent symptoms would be expected to
precede the reinstitution of antianginal treatment, cause and
effect are not self-evident. It is possible that those with a
restenotic lesion of lesser severity had no symptoms and
therefore did not receive medication, whereas those with a
more severe progressive lesion may have been treated with
escalating doses of antianginal agents. Although symptomatic
patients may be on more medication, it is also plausible that
patients on more treatment may have fewer symptoms. By
multivariate analysis, lesser lesion severity was in fact a
predictor of asymptomatic restenosis, suggesting that moder-
ate restenosis (lesion severity 50% to 60%) may often be
associated with no recurrent symptoms. Repeat intervention
on such lesions may not be warranted, because they are
associated with a good clinical outcome and may regress over
the next 2 to 5 years.28–30 Routine 6-month follow-up
TABLE 3. Patient Characteristics
BENESTENT I BENESTENT II pilot BENESTENT II DUET FINESS 2 FLARE MUSIC ROSE SOPHOS WEST I
No. of patients 516 203 827 210 156 1054 161 120 425 102
Age, y
Mean 57 58 58 60 60 60 59 58 59 61
Range 31–78 31–76 26–83 33–87 32–83 30–85 31–78 36–82 29–84 33–82
Male, % 81 84 79 80 81 82 82 80 74 81
Angina, %
Stable 58 68 51 68 54 83 50 48 53 84
Unstable 42 30 42 29 40 5 30 44 41 15
Silent 0 2 6 3 6 12 20 8 6 1
Diabetes, % 6 8 12 14 21 2 11 15 13 11
Previous MI, % 19 23 26 42 43 35 26 36 32 33
Previous CABG, % 1 3 2 3 4 5 3 4 3 2
Previous PTCA, % 3 6 7 15 16 9 9 22 12 4
MI indicates myocardial infarction.
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TABLE 4. Forty-Six Clinical and Angiographic Variables Analyzed for Univariate Predictors of Silent as
Opposed to Symptomatic Restenosis (>50% Diameter Stenosis)
Variable Asymptomatic Symptomatic OR 95% CI P
Age, y 59.9 59.2 0.39
Male sex 86.6 78.3 1.79 1.17–2.75 0.008
Hypertension 36.4 40.8 0.27
Diabetes mellitus 11.9 14.0 0.46
Smoking
Never 25.1 28.3 0.63
Ex-smoker 49.6 25.7
Current 25.4 46.0
Hypercholesterolemia 39.9 49.4 0.07
Family history of heart disease 33.3 35.2 0.67
Previous myocardial infarction 29.6 30.9 0.72
Pathological Q waves at screening 16.6 16.4 0.97
Previous PTCA 6.6 8.5 0.38
Previous CABG 1.5 3.7 0.095
Peripheral vascular disease 7.7 7.9 0.93
Multiple vessel disease 14.7 19.3 0.13
Angina status at screening
Silent 8.7 3.7 0.49
Stable 62.4 75.4
Unstable 29.0 21.0
-Blocker at screening 68.2 64.5 0.53
Nitrates at screening 64.2 66.4 0.72
Calcium channel blocker at screening 38.5 41.1 0.67
Aspirin at screening 93.2 91.2 0.57
Dipyridamole at screening 0.8 2.1 0.44
Heparin at screening 18.7 10.3 0.09
Coumarin/warfarin at screening 3.2 2.1 0.59
Diuretics at screening 5.8 8.8 0.36
ACE inhibitor at screening 18.7 27.5 0.11
Reference diameter preintervention, mm 2.83 2.76 0.07
Diameter stenosis preintervention, % 65.6 65.7 0.93
Preintervention MLD, mm 0.96 0.93 0.39
Left main lesion stenosis screening 0 1.1 0.99
LAD lesion stenosis screening 60.1 59.2 0.82
Circumflex lesion stenosis screening 25.5 31.5 0.11
RCA lesion stenosis screening 29.1 30.7 0.68
Reference diameter postintervention, mm 2.97 2.89 1.43 1.02–2.02 0.04
Pathological Q waves at discharge 16.8 16.2 0.87
Angina status at discharge




-Blocker at follow-up 50.0 61.3 0.17
Nitrates at follow-up 16.7 45.2 0.24 0.11–0.50 0.0002
Ca channel blocker at follow-up 26.0 43.6 0.46 0.23–0.90 0.02
Aspirin at follow-up 91.5 94.8 0.29
Dipyridamole at follow-up 41.9 40.5 0.82
Heparin at follow-up 0 1.9 0.99
Coumarin/warfarin at follow-up 7.0 5.8 0.78
Diuretics at follow-up 12.7 11.5 0.85
ACE inhibitor at follow-up 25.3 38.6 0.09
Pathological Q waves at follow-up 15.1 19.4 0.32
Reference diameter at follow-up, mm 2.91 2.77 1.61 1.17–2.240 0.004
Diameter stenosis at follow-up, % 62.4 66.6 0.98 0.97–0.99 0.0004
MLD at follow-up, mm 1.09 0.92 2.26 1.58–3.27 0.0001
LAD indicates left anterior descending coronary artery; RCA, right coronary artery. Values are percent except as given.
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angiography and resultant higher rates of repeat intervention
may be related to a lower 10-year mortality rate.7,31
The predictors of asymptomatic restenosis in the subgroup
undergoing stent deployment were absence of the use of
nitrates at 6-month follow-up and unstable angina at initial
presentation. It is possible that stents may have a “plaque-
stabilizing” effect in the relief of symptoms in acute coronary
syndromes (as opposed to stable angina).
An unexpected finding was that diabetes was not a predic-
tor of asymptomatic restenosis. Patients with diabetes are
more likely than those without to have suffered a silent
myocardial infarction and are less likely to have symptoms in
association with myocardial ischemia during treadmill stress
testing or Holter ECG, perhaps because of a sensory neurop-
athy.32,33 Conversely, one reason that those with diabetes may
have worse angina than those without is that diabetes is
associated with reduced collateral development.34 Such col-
lateral formation may be particularly important in the preven-
tion of angina when there is slow and progressive lesion
development, as occurs with restenosis. Hence, a lack of
collateral formation may offset a tendency toward reduced
symptoms from diabetic neuropathy, with diabetes having no
net effect on silent versus symptomatic restenosis.
Study Limitations
Although there was some standardization of clinical and
angiographic data collection, only the data common to all 10
study databases were included in the analysis. Collateral
vessel formation, which may have a significant bearing on the
presence or absence of symptoms associated with restenosis,
was not assessed in a standardized manner and thus could not
be analyzed.
Exclusion criteria for coronary interventional studies mean
that the study population is carefully selected and probably at
lower risk for restenosis than an unselected population of
patients. This may influence the rate of asymptomatic reste-
nosis and its predictors.
Conclusions
Men are more likely than women to have recurrent symptoms
if they develop restenosis after percutaneous coronary revas-
cularization. The only other multivariate predictor of recur-
rent symptoms was greater lesion severity at 6-month
follow-up angiography.
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